Search results
Results from the WOW.Com Content Network
Co-inventor of the Palmaz-Schatz Stent. Julio Palmaz (December 13, 1945 in La Plata , Argentina ) is a doctor of vascular radiology at University of Texas Health Science Center at San Antonio . He studied at the National University of La Plata in Argentina, earning his medical degree in 1971.
Stent technology improved rapidly, and in 1989 the Palmaz-Schatz balloon-expandable intracoronary stent was developed. [24] [25] Initial results with the Palmaz-Schatz stents were excellent when compared to balloon angioplasty, with a significantly lower incidence of abrupt closure and peri-procedure heart attack. [26]
Shortly thereafter, in 1987, Julio Palmaz (known for patenting a balloon-expandable stent [20]) and Richard Schatz implanted their similar stent into a patient in Germany. Though several doctors have been credited with the creation of the stent, the first FDA-approved stent in the U.S. was created by Richard Schatz and coworkers.
The first device was simple, according to Parodi: “It was a graft I designed with expandable ends, the extra-large Palmaz stent, a Teflon sheath with a valve, a wire, and the valvuplasty balloon, which I took from the cardiologists." Juan Parodi invited Julio Palmaz to participate in the case at the Instituto Cardiovascular de Buenos Aires.
It was first used in a human patient by Dr. Ronald Colapinto, of the University of Toronto, in 1982, but did not become reproducibly successful until the development of endovascular stents in 1985. In 1988 the first successful TIPS was realized by M. Rössle, G.M. Richter, G. Nöldge and J. Palmaz at the University of Freiburg. [1]
The vast majority of stents used in modern interventional cardiology are drug-eluting stents (DES). They are used in a medical procedure called percutaneous coronary intervention (PCI). Coronary stents are divided into two broad types: drug-eluting and bare metal stents. As of 2023, drug-eluting stents were used in more than 90% of all PCI ...
Most current FDA-approved drug-eluting stents use sirolimus (also known as rapamycin), everolimus and zotarolimus. Biolimus A9-eluting stents, which utilize biodegradable polymers, are approved outside the U.S. [27] Newer-generation PCI technologies aim to reduce the risk of late stent thrombosis or other long-term adverse events.
Guidelines and indications are specific to different patient populations. For adults with aortic stenosis, guidelines suggest that balloon aortic valvuloplasty (BAV) is to be used as a temporary procedure to improve blood flow through the aortic valve to alleviate symptoms and stabilize clinically before having more invasive procedures done, including aortic valve replacement (AVR) or ...